<pmc-articleset>
  <article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" xml:lang="en" dtd-version="1.4">
    <!--The publisher of this article does not allow downloading of the full text in XML form.-->
    <front>
      <journal-meta>
        <journal-id journal-id-type="nlm-ta">J Clin Invest</journal-id>
        <journal-id journal-id-type="iso-abbrev">J. Clin. Invest</journal-id>
        <journal-id journal-id-type="pmc-domain-id">120</journal-id>
        <journal-id journal-id-type="pmc-domain">jcinvest</journal-id>
        <journal-id journal-id-type="publisher-id">J Clin Invest</journal-id>
        <journal-title-group>
          <journal-title>The Journal of Clinical Investigation</journal-title>
        </journal-title-group>
        <issn pub-type="ppub">0021-9738</issn>
        <issn pub-type="epub">1558-8238</issn>
        <publisher>
          <publisher-name>American Society for Clinical Investigation</publisher-name>
        </publisher>
      </journal-meta>
      <article-meta>
        <article-id pub-id-type="pmcid">PMC6763222</article-id>
        <article-id pub-id-type="pmcid-ver">PMC6763222.1</article-id>
        <article-id pub-id-type="pmcaid">6763222</article-id>
        <article-id pub-id-type="pmcaiid">6763222</article-id>
        <article-id pub-id-type="pmid">31483290</article-id>
        <article-id pub-id-type="doi">10.1172/JCI128227</article-id>
        <article-id pub-id-type="publisher-id">128227</article-id>
        <article-version article-version-type="pmc-version">1</article-version>
        <article-categories>
          <subj-group subj-group-type="heading">
            <subject>Clinical Medicine</subject>
          </subj-group>
        </article-categories>
        <title-group>
          <article-title>Genetic hallmarks of recurrent/metastatic adenoid cystic carcinoma</article-title>
        </title-group>
        <contrib-group>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Ho</surname>
              <given-names initials="AS">Allen S.</given-names>
            </name>
            <xref ref-type="aff" rid="A1">1</xref>
            <xref ref-type="aff" rid="A2">2</xref>
          </contrib>
          <contrib contrib-type="author">
            <contrib-id contrib-id-type="orcid" authenticated="true">http://orcid.org/0000-0003-0615-1654</contrib-id>
            <name name-style="western">
              <surname>Ochoa</surname>
              <given-names initials="A">Angelica</given-names>
            </name>
            <email>ochoaa@mskcc.org</email>
            <xref ref-type="aff" rid="A3">3</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Jayakumaran</surname>
              <given-names initials="G">Gowtham</given-names>
            </name>
            <email>jayakumg@mskcc.org</email>
            <xref ref-type="aff" rid="A4">4</xref>
          </contrib>
          <contrib contrib-type="author">
            <contrib-id contrib-id-type="orcid" authenticated="true">http://orcid.org/0000-0001-5406-4104</contrib-id>
            <name name-style="western">
              <surname>Zehir</surname>
              <given-names initials="A">Ahmet</given-names>
            </name>
            <email>zehira@mskcc.org</email>
            <xref ref-type="aff" rid="A4">4</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Valero Mayor</surname>
              <given-names initials="C">Cristina</given-names>
            </name>
            <xref ref-type="aff" rid="A5">5</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Tepe</surname>
              <given-names initials="J">Justin</given-names>
            </name>
            <xref ref-type="aff" rid="A5">5</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Makarov</surname>
              <given-names initials="V">Vladimir</given-names>
            </name>
            <email>makarovv@mskcc.org</email>
            <xref ref-type="aff" rid="A6">6</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Dalin</surname>
              <given-names initials="MG">Martin G.</given-names>
            </name>
            <email>martin.dalin@gu.se</email>
            <xref ref-type="aff" rid="A6">6</xref>
          </contrib>
          <contrib contrib-type="author">
            <contrib-id contrib-id-type="orcid" authenticated="true">http://orcid.org/0000-0002-1326-4166</contrib-id>
            <name name-style="western">
              <surname>He</surname>
              <given-names initials="J">Jie</given-names>
            </name>
            <email>Jhe@foundationmedicine.com</email>
            <xref ref-type="aff" rid="A7">7</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Bailey</surname>
              <given-names initials="M">Mark</given-names>
            </name>
            <email>markibail@gmail.com</email>
            <xref ref-type="aff" rid="A7">7</xref>
          </contrib>
          <contrib contrib-type="author">
            <contrib-id contrib-id-type="orcid" authenticated="true">http://orcid.org/0000-0001-9155-556X</contrib-id>
            <name name-style="western">
              <surname>Montesion</surname>
              <given-names initials="M">Meagan</given-names>
            </name>
            <email>mmontesion@foundationmedicine.com</email>
            <xref ref-type="aff" rid="A7">7</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Ross</surname>
              <given-names initials="JS">Jeffrey S.</given-names>
            </name>
            <xref ref-type="aff" rid="A7">7</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Miller</surname>
              <given-names initials="VA">Vincent A.</given-names>
            </name>
            <email>vmiller@foundationmedicine.com</email>
            <xref ref-type="aff" rid="A7">7</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Chan</surname>
              <given-names initials="L">Lindsay</given-names>
            </name>
            <xref ref-type="aff" rid="A7">7</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Ganly</surname>
              <given-names initials="I">Ian</given-names>
            </name>
            <email>ganlyi@mskcc.org</email>
            <xref ref-type="aff" rid="A5">5</xref>
          </contrib>
          <contrib contrib-type="author">
            <contrib-id contrib-id-type="orcid" authenticated="true">http://orcid.org/0000-0002-4905-8946</contrib-id>
            <name name-style="western">
              <surname>Dogan</surname>
              <given-names initials="S">Snjezana</given-names>
            </name>
            <email>dogans@mskcc.org</email>
            <xref ref-type="aff" rid="A4">4</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Katabi</surname>
              <given-names initials="N">Nora</given-names>
            </name>
            <email>katabin@mskcc.org</email>
            <xref ref-type="aff" rid="A4">4</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Tsipouras</surname>
              <given-names initials="P">Petros</given-names>
            </name>
            <email>Petros.tsipouras@gmail.com</email>
            <xref ref-type="aff" rid="A8">8</xref>
          </contrib>
          <contrib contrib-type="author">
            <contrib-id contrib-id-type="orcid" authenticated="true">http://orcid.org/0000-0003-0306-6147</contrib-id>
            <name name-style="western">
              <surname>Ha</surname>
              <given-names initials="P">Patrick</given-names>
            </name>
            <email>patrick.ha@ucsf.edu</email>
            <xref ref-type="aff" rid="A9">9</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Agrawal</surname>
              <given-names initials="N">Nishant</given-names>
            </name>
            <email>nagrawal@surgery.bsd.uchicago.edu</email>
            <xref ref-type="aff" rid="A10">10</xref>
          </contrib>
          <contrib contrib-type="author">
            <contrib-id contrib-id-type="orcid" authenticated="true">http://orcid.org/0000-0002-6614-802X</contrib-id>
            <name name-style="western">
              <surname>Solit</surname>
              <given-names initials="DB">David B.</given-names>
            </name>
            <email>solitd@mskcc.org</email>
            <xref ref-type="aff" rid="A3">3</xref>
            <xref ref-type="aff" rid="A5">5</xref>
            <xref ref-type="aff" rid="A14">14</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Futreal</surname>
              <given-names initials="PA">P. Andrew</given-names>
            </name>
            <email>AFutreal@mdanderson.org</email>
            <xref ref-type="aff" rid="A11">11</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>El Naggar</surname>
              <given-names initials="AK">Adel K.</given-names>
            </name>
            <xref ref-type="aff" rid="A12">12</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Reis-Filho</surname>
              <given-names initials="JS">Jorge S.</given-names>
            </name>
            <xref ref-type="aff" rid="A13">13</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Weigelt</surname>
              <given-names initials="B">Britta</given-names>
            </name>
            <email>weigeltb@mskcc.org</email>
            <xref ref-type="aff" rid="A13">13</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Ho</surname>
              <given-names initials="AL">Alan L.</given-names>
            </name>
            <email>hoa@mskcc.org</email>
            <xref ref-type="aff" rid="A14">14</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Schultz</surname>
              <given-names initials="N">Nikolaus</given-names>
            </name>
            <email>schultzn@mskcc.org</email>
            <xref ref-type="aff" rid="A3">3</xref>
            <xref ref-type="aff" rid="A6">6</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Chan</surname>
              <given-names initials="TA">Timothy A.</given-names>
            </name>
            <xref ref-type="aff" rid="A6">6</xref>
            <xref ref-type="aff" rid="A15">15</xref>
            <xref ref-type="aff" rid="A16">16</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Morris</surname>
              <given-names initials="LGT">Luc G.T.</given-names>
            </name>
            <xref ref-type="aff" rid="A5">5</xref>
            <xref ref-type="aff" rid="A6">6</xref>
            <xref ref-type="aff" rid="A16">16</xref>
          </contrib>
        </contrib-group>
        <aff id="A1"><label>1</label>Department of Surgery and</aff>
        <aff id="A2"><label>2</label>Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, California, USA.</aff>
        <aff id="A3"><label>3</label>Marie-Josée and Henry R. Kravis Center for Molecular Oncology,</aff>
        <aff id="A4"><label>4</label>Diagnostic Molecular Pathology,</aff>
        <aff id="A5"><label>5</label>Head and Neck Service, Department of Surgery, and</aff>
        <aff id="A6"><label>6</label>Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center (MSKCC), New York, New York, USA.</aff>
        <aff id="A7"><label>7</label>Foundation Medicine, Cambridge, Massachusetts, USA.</aff>
        <aff id="A8"><label>8</label>Department of Genetics, Yale University School of Medicine, New Haven, Connecticut, USA.</aff>
        <aff id="A9"><label>9</label>Department of Otolaryngology–Head and Neck Surgery, UCSF, San Francisco, California, USA.</aff>
        <aff id="A10"><label>10</label>Department of Surgery, University of Chicago, Chicago, Illinois, USA.</aff>
        <aff id="A11"><label>11</label>Department of Genomic Medicine and</aff>
        <aff id="A12"><label>12</label>Department of Pathology, University of Texas MD Anderson Cancer Center (MDACC), Houston, Texas, USA.</aff>
        <aff id="A13"><label>13</label>Experimental Pathology Service, MSKCC, New York, New York, USA.</aff>
        <aff id="A14"><label>14</label>Department of Medicine,</aff>
        <aff id="A15"><label>15</label>Department of Radiation Oncology, and</aff>
        <aff id="A16"><label>16</label>Immunogenomics and Precision Oncology Platform, MSKCC, New York, New York, USA.</aff>
        <author-notes>
          <corresp>Address correspondence to: Nikolaus Schultz, Timothy A. Chan, and Luc G.T. Morris, Immunogenomics and Precision Oncology Platform, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, New York 10065, USA. Phone: 212.639.3049; Email: <email>schultzn@mskcc.org</email>, <email>chant@mskcc.org</email>, <email>morrisl@mskcc.org</email>.</corresp>
          <fn>
            <p><bold>Authorship note:</bold> ASH and AO contributed equally to the manuscript.</p>
          </fn>
          <fn fn-type="COI-statement">
            <p><bold>Conflict of interest:</bold> ALH received funding from Eisai, Bristol-Myers Squibb, Kura Oncology, AstraZeneca, Genentech/Roche, Celldex Therapeutics, Pfizer, Lilly, and Bayer; consulting fees from Bristol-Myers Squibb, Merck, Novartis, AstraZeneca, Regeneron, Sanofi Aventis, Sun Pharma, Eisai, Genentech/Roche, Sanofi Genzyme, and Ayala; and travel reimbursement from Ignyta and Kura Oncology. PH received funding from Stryker, Ethicon, and Medtronic; consulting fees from Loxo/Bayer Oncology; and travel reimbursement from Genentech. DBS received consulting fees from Pfizer, Loxo Oncology, Lilly Oncology, Illumina, Intezyne, and Vividion Therapeutics. JH, MB, MM, JSR, VAM, and LC are employees of Foundation Medicine. JSRF serves on the scientific advisory boards of Volition RX, Paige.AI, Roche Tissue Diagnostics, Ventana, Genentech, InVicro, and Novartis; and received consulting fees from Goldman Sachs (Merchant Banking) and REPARE Therapeutics. TAC is a cofounder of and holds equity in Gritstone Oncology and received research funding from Bristol-Myers Squibb, Eisai, AstraZeneca, and Illumina. LGTM received research funding from Bristol-Myers Squibb, Illumina and AstraZeneca.</p>
          </fn>
        </author-notes>
        <pub-date date-type="pub" publication-format="electronic" iso-8601-date="2019-09-04T16:00:00-0400">
          <day>4</day>
          <month>9</month>
          <year>2019</year>
        </pub-date>
        <pub-date date-type="collection" publication-format="electronic" iso-8601-date="2019-09-04T16:00:00-0400">
          <day>4</day>
          <month>9</month>
          <year>2019</year>
        </pub-date>
        <pub-date date-type="pub" publication-format="print" iso-8601-date="2019-10-01T16:00:00-0400">
          <day>1</day>
          <month>10</month>
          <year>2019</year>
        </pub-date>
        <volume>129</volume>
        <issue>10</issue>
        <issue-id pub-id-type="pmc-issue-id">342797</issue-id>
        <fpage>4276</fpage>
        <lpage>4289</lpage>
        <history>
          <date date-type="received">
            <day>20</day>
            <month>2</month>
            <year>2019</year>
          </date>
          <date date-type="accepted">
            <day>9</day>
            <month>7</month>
            <year>2019</year>
          </date>
        </history>
        <pub-history>
          <event event-type="pmc-release">
            <date>
              <day>01</day>
              <month>01</month>
              <year>2020</year>
            </date>
          </event>
          <event event-type="pmc-live">
            <date>
              <day>01</day>
              <month>01</month>
              <year>2020</year>
            </date>
          </event>
          <event event-type="pmc-last-change">
            <date iso-8601-date="2020-01-01 00:43:16.627">
              <day>01</day>
              <month>01</month>
              <year>2020</year>
            </date>
          </event>
        </pub-history>
        <permissions>
          <copyright-statement>© 2019 American Society for Clinical Investigation</copyright-statement>
          <copyright-year>2019</copyright-year>
          <copyright-holder>American Society for Clinical Investigation</copyright-holder>
        </permissions>
        <self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="jci-129-128227.pdf"/>
        <self-uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.jci.org/articles/view/128227">This article is available online at https://www.jci.org/articles/view/128227</self-uri>
        <abstract>
          <sec>
            <title>BACKGROUND</title>
            <p>Adenoid cystic carcinoma (ACC) is a rare malignancy arising in salivary glands and other sites, characterized by high rates of relapse and distant spread. Recurrent/metastatic (R/M) ACCs are generally incurable, due to a lack of active systemic therapies. To improve outcomes, deeper understanding of genetic alterations and vulnerabilities in R/M tumors is needed.</p>
          </sec>
          <sec>
            <title>METHODS</title>
            <p>An integrated genomic analysis of 1,045 ACCs (177 primary, 868 R/M) was performed to identify alterations associated with advanced and metastatic tumors. Intratumoral genetic heterogeneity, germline mutations, and therapeutic actionability were assessed.</p>
          </sec>
          <sec>
            <title>RESULTS</title>
            <p>Compared with primary tumors, R/M tumors were enriched for alterations in key Notch (<italic toggle="yes">NOTCH1</italic>, 26.3% vs. 8.5%; <italic toggle="yes">NOTCH2</italic>, 4.6% vs. 2.3%; <italic toggle="yes">NOTCH3</italic>, 5.7% vs. 2.3%; <italic toggle="yes">NOTCH4</italic>, 3.6% vs. 0.6%) and chromatin-remodeling (<italic toggle="yes">KDM6A</italic>, 15.2% vs. 3.4%; <italic toggle="yes">KMT2C/MLL3</italic>, 14.3% vs. 4.0%; <italic toggle="yes">ARID1B</italic>, 14.1% vs. 4.0%) genes. <italic toggle="yes">TERT</italic> promoter mutations (13.1% of R/M cases) were mutually exclusive with both <italic toggle="yes">NOTCH1</italic> mutations (<italic toggle="yes">q</italic> = 3.3 × 10<sup>–4</sup>) and <italic toggle="yes">MYB/MYBL1</italic> fusions (<italic toggle="yes">q</italic> = 5.6 × 10<sup>–3</sup>), suggesting discrete, alternative mechanisms of tumorigenesis. This network of alterations defined 4 distinct ACC subgroups: <italic toggle="yes">MYB<sup>+</sup>NOTCH1<sup>+</sup></italic>, <italic toggle="yes">MYB<sup>+</sup>/other</italic>, <italic toggle="yes">MYB<sup>WT</sup>NOTCH1<sup>+</sup></italic>, and <italic toggle="yes">MYB<sup>WT</sup>TERT<sup>+</sup></italic>. Despite low mutational load, we identified numerous samples with marked intratumoral genetic heterogeneity, including branching evolution across multiregion sequencing.</p>
          </sec>
          <sec>
            <title>CONCLUSION</title>
            <p>These observations collectively redefine the molecular underpinnings of ACC progression and identify further targets for precision therapies.</p>
          </sec>
          <sec>
            <title>FUNDING</title>
            <p>Adenoid Cystic Carcinoma Research Foundation, Pershing Square Sohn Cancer Research grant, the PaineWebber Chair, Stand Up 2 Cancer, NIH R01 CA205426, the STARR Cancer Consortium, NCI R35 CA232097, the Frederick Adler Chair, Cycle for Survival, the Jayme Flowers Fund, The Sebastian Nativo Fund, NIH K08 DE024774 and R01 DE027738, and MSKCC through NIH/NCI Cancer Center Support Grant (P30 CA008748).</p>
          </sec>
        </abstract>
        <kwd-group kwd-group-type="specialties">
          <kwd>Oncology</kwd>
        </kwd-group>
        <kwd-group kwd-group-type="keywords">
          <kwd>Head and neck cancer</kwd>
        </kwd-group>
        <funding-group>
          <award-group>
            <funding-source>Adenoid Cystic Carcinoma Research Foundation</funding-source>
            <award-id>2015</award-id>
          </award-group>
          <award-group>
            <funding-source>Pershing Square Sohn Cancer Research Grant</funding-source>
            <award-id>2018</award-id>
          </award-group>
          <award-group>
            <funding-source>PainWebber Chair</funding-source>
            <award-id>2016</award-id>
          </award-group>
          <award-group>
            <funding-source>Stand Up 2 Cancer</funding-source>
            <award-id>2016</award-id>
          </award-group>
          <award-group>
            <funding-source>
              <institution-wrap>
                <institution>National Institutes of Health</institution>
                <institution-id>https://doi.org/10.13039/100000002</institution-id>
              </institution-wrap>
            </funding-source>
            <award-id>R01 CA205426</award-id>
          </award-group>
          <award-group>
            <funding-source>
              <institution-wrap>
                <institution>National Cancer Institute</institution>
                <institution-id>https://doi.org/10.13039/100000054</institution-id>
              </institution-wrap>
            </funding-source>
            <award-id>R35 CA232097</award-id>
          </award-group>
          <award-group>
            <funding-source>STARR Cancer Consortium</funding-source>
            <award-id>2017</award-id>
          </award-group>
          <award-group>
            <funding-source>Frederick Adler Chair</funding-source>
            <award-id>2016</award-id>
          </award-group>
          <award-group>
            <funding-source>Cycle for Survival</funding-source>
            <award-id>2017</award-id>
          </award-group>
          <award-group>
            <funding-source>
              <institution-wrap>
                <institution>National Institutes of Health</institution>
                <institution-id>https://doi.org/10.13039/100000002</institution-id>
              </institution-wrap>
            </funding-source>
            <award-id>K08 DE024774</award-id>
          </award-group>
          <award-group>
            <funding-source>
              <institution-wrap>
                <institution>National Institutes of Health</institution>
                <institution-id>https://doi.org/10.13039/100000002</institution-id>
              </institution-wrap>
            </funding-source>
            <award-id>R01 DE027738</award-id>
          </award-group>
          <award-group>
            <funding-source>NIH/NCI Cancer Center Support Grant</funding-source>
            <award-id>P30 CA008748</award-id>
          </award-group>
          <award-group>
            <funding-source>The Jayme Flowers Fund</funding-source>
            <award-id>2018</award-id>
          </award-group>
          <award-group>
            <funding-source>The Sebastian Nativo Fund</funding-source>
            <award-id>2018</award-id>
          </award-group>
        </funding-group>
        <custom-meta-group>
          <custom-meta>
            <meta-name>pmc-status-qastatus</meta-name>
            <meta-value>0</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-status-live</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-status-embargo</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-status-released</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-open-access</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-olf</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-manuscript</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-legally-suppressed</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-has-pdf</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-has-supplement</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-pdf-only</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-suppress-copyright</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-is-real-version</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-is-scanned-article</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-preprint</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-in-epmc</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
        </custom-meta-group>
      </article-meta>
    </front>
  </article>
</pmc-articleset>
